CXCL10 and prostate carcinoma: Akin to the findings in the pancreatic cancer trial that was conducted with the same adenoviral vector [19], in this study involving recurrent prostate cancer we observed similar trends in cytokine concentrations i.e., increase in serum IL-12, IFNγ and CXCL10 with increased adenoviral doses (Fig 4).